Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 6/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.36 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.35 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.35 |
| ▸ | MAP1LC3A | Q9H492 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6091171 | 0.93 | KDM4E (0.39) | TP53RXFP1KDM4EIRAK4PTGER1 | |
| SCHEMBL6093283 | 0.92 | KDM4E (0.39) | TP53RXFP1KDM4EIRAK4PTGER1 | |
| SCHEMBL6093287 | 0.92 | KDM4E (0.37) | TP53RXFP1KDM4EIRAK4MAPT | |
| SCHEMBL6093291 | 0.92 | KDM4E (0.39) | RXFP1KDM4EIRAK4PTGER1 | |
| SCHEMBL6092716 | 0.89 | TP53 (0.42) | TP53PTGESRXFP1ELANEKDM4E | |
| SCHEMBL5798590 | 0.87 | L3MBTL1 (0.43) | TP53IRAK4 | |
| SCHEMBL6092717 | 0.86 | RXFP1 (0.40) | TP53PTGESRXFP1MAPT | |
| SCHEMBL6090346 | 0.84 | MAPT (0.42) | TP53RXFP1MAPTPOLB | |
| SCHEMBL5738325 | 0.81 | TP53 (0.46) | TP53PTGESRXFP1MAPK8MAPT | |
| SCHEMBL6091080 | 0.81 | HDAC1 (0.42) | TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160879-A1 | Indoles useful in the treatment of inflammation | BIOLIPOX AB (SE) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160879-A1 | Indoles useful in the treatment of inflammation | IDO1, PTGS1, IDO2 | TP53 2032/4885PTGES 4/4885RXFP1 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.